DuPont Launches AmberChrom SIL Silica Gel for Peptide Purification

DuPont has launched DuPont AmberChrom SIL silica gel, a reverse phase silica-based chromatography medium in C8 and C18 chemistries for purifying peptide therapeutics, including GLP-1 receptor agonists. The media covers multiple purification stages, from crude purification through final high-purity polishing. Application studies show it can be used alone or combined with AmberChrom XT chromatography resins, alongside AmberChrom TQ1 and CG resins, to support purity, yield and recovery targets.

Key facts

Market context

Silica gel chromatography media are porous materials used to separate molecules by size, polarity or hydrophobicity during purification. Reverse phase silica, typically bonded with alkyl chains such as C8 or C18, retains hydrophobic compounds and lets them be eluted in controlled gradients, which makes it a workhorse for purifying small molecules and peptides. Demand for peptide therapeutics has grown with injectable drugs for diabetes, obesity and some cancers, and GLP-1 receptor agonists are among the highest-volume examples. Peptide manufacturing is demanding because synthesis produces closely related impurities that must be removed to reach high purity. Producers therefore rely on multi-step purification trains that often combine silica media with polymeric resins. Suppliers of chromatography media compete on purity, column consistency, throughput and the ability to integrate with existing resin platforms, and new product launches in this area typically aim to give manufacturers more options within a single purification workflow.

Source: official release on dupont.com. Summary and context written by Market Krystal.